Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer

Technology appraisal guidance
Reference number: TA214
Published: 23 February 2011

TA214 Breast cancer - bevacizumab (in combination with a taxane): GE decision paper September 2013

TA214 Breast cancer - bevacizumab (in combination with a taxane): GE decision paper September 2013

TA214 Breast cancer - bevacizumab (in combination with a taxane): GE decision paper September 2013
23 September 2013
(106.59 Kb 31 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 18 September 2013